Treating Demodex Blepharitis: Resource Burden, Patient Experience, and the Path Forward

Prof. Nanavaty reviews current treatment patterns in the UK, noting the lack of any therapy directed specifically at Demodex and the resulting strain on healthcare resources. He explores how undiagnosed Demodex blepharitis contributes to treatment resistance, ocular surface instability, and complications in surgical planning for cataract and refractive procedures. Drawing on patient survey data, he highlights the burden of prolonged symptoms and frequent follow-ups, and outlines practical steps clinicians can take to improve diagnosis and target treatment more effectively.